Efficacy and safety of celiac plexus radiotherapy in Pancreatic cancer-related pain management: a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
141 participants, median age 64.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Celiac plexus radiotherapy appears effective in reducing cancer-related pain at 3- and 6-week post-procedure with minimal impact on morphine use. It demonstrates a favorable safety profile, making it a promising option for managing advanced cancer pain.
[BACKGROUND] Advanced cancer pain, especially in pancreatic cancer, often requires interventional management.
- 95% CI -7.77 to -1.42
- 연구 설계 meta-analysis
APA
Osama M, Khan H, et al. (2025). Efficacy and safety of celiac plexus radiotherapy in Pancreatic cancer-related pain management: a systematic review and meta-analysis.. Annals of medicine and surgery (2012), 87(12), 8770-8778. https://doi.org/10.1097/MS9.0000000000004120
MLA
Osama M, et al.. "Efficacy and safety of celiac plexus radiotherapy in Pancreatic cancer-related pain management: a systematic review and meta-analysis.." Annals of medicine and surgery (2012), vol. 87, no. 12, 2025, pp. 8770-8778.
PMID
41377352
Abstract
[BACKGROUND] Advanced cancer pain, especially in pancreatic cancer, often requires interventional management. This meta-analysis evaluates the effectiveness and safety of celiac plexus radiotherapy in reducing pain, providing comprehensive insights for oncologic pain management.
[METHODS] A systematic search was conducted on PubMed, Embase, and Cochrane databases through October 2024. The primary outcome was the BPI-SF (Brief Pain Inventory-Short Form) pain score reduction at 3 weeks. Data were analyzed using random-effects models, with heterogeneity assessed by statistics and publication bias evaluated via funnel plots, all conducted in R software 4.3.3.
[RESULTS] This meta-analysis included 4 randomized controlled trials with 141 participants, median age 64.25 years. Most patients (91.75%) had pancreatic cancer. BPI-SF pain scores showed significant reductions at 3 weeks (RR -4.59, 95% CI: -7.77 to -1.42, < 0.001, = 99%) and at 6 weeks (RR -2.35, 95% CI: -4.16 to -0.63, < 0.01, = 98%). Morphine use showed no significant change at 3-week post-procedure. Celiac plexus radiosurgery demonstrated a favorable safety profile, with mild-to-moderate adverse events like fatigue (59.5%), abdominal pain (38%), and nausea (40.3%), and a few severe events (28% abdominal pain).
[CONCLUSION] Celiac plexus radiotherapy appears effective in reducing cancer-related pain at 3- and 6-week post-procedure with minimal impact on morphine use. It demonstrates a favorable safety profile, making it a promising option for managing advanced cancer pain.
[METHODS] A systematic search was conducted on PubMed, Embase, and Cochrane databases through October 2024. The primary outcome was the BPI-SF (Brief Pain Inventory-Short Form) pain score reduction at 3 weeks. Data were analyzed using random-effects models, with heterogeneity assessed by statistics and publication bias evaluated via funnel plots, all conducted in R software 4.3.3.
[RESULTS] This meta-analysis included 4 randomized controlled trials with 141 participants, median age 64.25 years. Most patients (91.75%) had pancreatic cancer. BPI-SF pain scores showed significant reductions at 3 weeks (RR -4.59, 95% CI: -7.77 to -1.42, < 0.001, = 99%) and at 6 weeks (RR -2.35, 95% CI: -4.16 to -0.63, < 0.01, = 98%). Morphine use showed no significant change at 3-week post-procedure. Celiac plexus radiosurgery demonstrated a favorable safety profile, with mild-to-moderate adverse events like fatigue (59.5%), abdominal pain (38%), and nausea (40.3%), and a few severe events (28% abdominal pain).
[CONCLUSION] Celiac plexus radiotherapy appears effective in reducing cancer-related pain at 3- and 6-week post-procedure with minimal impact on morphine use. It demonstrates a favorable safety profile, making it a promising option for managing advanced cancer pain.